Skip to main content
OpenTrials
Completed

NCT Number: NCT05652959

Real-world Performance and Safety of Cerviron® in the Treatment of Vaginitis

Vaginitis is a broad term that includes a range of gynecological disorders characterized by infection of vaginal mucosa, inflammation of vulva and alteration of the normal vaginal microflora. The most prevalent is bacterial vaginosis, followed by other clinical entities such as candidiasis, trichomoniasis and non-specific vaginitis.

A collection of clinical data was conducted to assess the tolerability of Cerviron® ovules in the treatment and management of various types of vaginitis in clinical practice. A total of 111 women aged between 20 and 70 years were recruited, 71 of whom were treated with Cerviron® ovules as monotherapy and 40 who used Cerviron® ovules as supportive treatment in conjunction with antibiotic therapy. The aim of our study was to assess the relief in vaginal symptoms and changes in the normal vaginal pH level after 3 months of treatment with Cerviron® medical device in real-life clinical practice settings.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vaginitis Bacterial Infections Bacterial Infections and Mycoses Bacterial Vaginosis Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Infections Urogenital Diseases Vaginal Discharge Vaginal Diseases Vaginosis, Bacterial Vulvar Diseases Vulvitis Vulvovaginitis

Age range

18 year–65 year

Sex eligibility

Female

Study type

Observational

Primary location

Spitalul Clinic Dr. Ion Cantacuzino Bucharest, Bucharest, Romania

Loading trial locations.

About this study

This study was designed as real-world evidence study with the primary purpose to assess the performance and tolerance of Cerviron® ovules in the treatment and management of various types of vulvovaginitis. The study collected clinical data from 28 different specialized gynecology clinical facilities. The study was conducted between May 20, 2021 and August 31, 2021.

The primary objective of this study was to assess the tolerability of Cerviron® ovules in the treatment and management of various types of vulvovaginitis, but also to confirm its performance both on symptoms relief and as a user-friendly device. The secondary objective of this study was to assess the performance of the medical device by clinical exam and patients' degree of satisfaction. The study design consisted of 3 or 4 visits over 90 ± 3 days. Cerviron® ovules were applied intravaginally, once per day, on the first day after menstruation and for 15 days during 3 consecutive months.

Data of 111 women aged between 20 and 70 years were analyzed, 71 of whom were treated with Cerviron® ovules as monotherapy and 40 who used Cerviron® ovules as supportive treatment in conjunction with anti-infectious therapy.

The symptoms recorded in the medical charts were followed to determine the performance of the medical device during the treatment.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult females with a diagnosis of infectious or non-infectious vaginitis and treated with Cerviron® with or without anti-infectious treatment for at least three months:
  • Negative result for Gardnerella vaginalis, Candida albicans, Trichomonas vaginalis.

Exclusion criteria

  • Subjects with diagnosed abnormal genital bleeding;
  • Subject with vulvar, vaginal or cervical cancer;
  • Subjects with other inflammatory gynecological conditions.

Treatment and study plan

Cerviron®

Device

Cerviron® is a medical device manufactured by PFC Pharma Manufacturing SL formulated following the provisions of the European Regulation 2017/745 on Medical Devices. Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21. Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.

Primary outcomes

  1. Safety of the medical device

    Time frame: 3 months

    the number of possible adverse Number of reactions observed during the treatment

Secondary outcomes

  1. Improvement in the vaginal discharge aspect

    Time frame: 3 months

    Presence/absence of abnormal/normal vaginal discharge

  2. Improvement in the association of vaginal symptoms (burn and pain)

    Time frame: 3 months

    Presence/absence of vaginal symptoms (burn and pain)

  3. Improvement in vaginal irritation

    Time frame: 3 months

    Presence/absence of vaginal irritation

  4. Measurement of vaginal pH

    Time frame: 3 months

    Normalization of vaginal pH values

Sponsors and collaborators

Lead sponsor

Perfect Care Distribution

Industry

Collaborators

  • MDX Research

Registry information

Official study title

Real-world Performance and Safety of Cerviron® Medical Device in the Treatment of Various Types of Vaginitis

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Dec 15, 2022
Registry last updated
Apr 19, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.